15
Feb, 2022
European RBDCOV project to study HIPRA’s COVID-19 vaccine in children adolescents and immunocompromised patients
Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein. “RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) is a new Horizon Europe project led by the biotech pharmaceutical company HIPRA. Launched on 1st December, RBDCOV project objective is to test the efficacy, tolerability, and safety of the HIPRA’s recombinant Covid-19 vaccine in children (including adolescents) and immunocompromised people. The trials will last 2.5 years. […]